SEOUL, South Korea I November 6, 2024 I Hanmi Pharm. Co., Ltd. has announced promising research results for its novel obesity treatment, HM17321. This groundbreaking drug not only augments fat loss ...
PARIS, France and TARRYTOWN, NY, USA I 6, 2024 I The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis ...
November 04, 2024 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK ...
-Interim readout expected in second half of 2025 and completion of Phase 1/2 study anticipated in 2026 CAMBRIDGE, MA, USA I November 04, 2024 I Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a ...
Research collaboration to leverage Surrozen’s antibody research capabilities and expertise to discover a potential first in class treatment for patients with Idiopathic Pulmonary Fibrosis SOUTH SAN ...
SHANGHAI, China and CLINTON, NJ, USA I November 4, 2024 I HuidaGene Therapeutics (“HuidaGene”), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its ...
The Phase 2 study will evaluate the efficacy, safety and tolerability of the company’s lead lipidated IL-22 analogue, CK-0045, in patients with obesity and type 2 diabetes COPENHAGEN, Denmark I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback